Biocon Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Biocon Ltd is ₹ 359.55 as of 30 Apr 15:30 . The P/E Ratio of Biocon Ltd changed from 66.3 on March 2021 to 40.4 on March 2025 . This represents a CAGR of -9.43% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Biocon Ltd changed from ₹ 49056 crore on March 2021 to ₹ 40964 crore on March 2025 . This represents a CAGR of -3.54% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Biocon Ltd for the Dec '25 is ₹ 4290 crore as compare to the Sep '25 revenue of ₹ 4388 crore. This represent the decline of -2.24% The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The ebitda of Biocon Ltd for the Dec '25 is ₹ 657.4 crore as compare to the Sep '25 ebitda of ₹ 916.5 crore. This represent the decline of -28.27% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ -51.8 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Biocon Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Biocon Ltd or Medicamen Biotech Ltd?

Market cap of Biocon Ltd is 58,279 Cr while Market cap of Medicamen Biotech Ltd is 343 Cr

What are the key factors driving the stock performance of Biocon Ltd and Medicamen Biotech Ltd?

The stock performance of Biocon Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Medicamen Biotech Ltd?

As of May 4, 2026, the Biocon Ltd stock price is INR ₹359.55. On the other hand, Medicamen Biotech Ltd stock price is INR ₹253.3.

How do dividend payouts of Biocon Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Biocon Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.